Rheolytic thrombectomy with AngioJet in thrombus-containing lesions

Mandeep Singh, Daniel J. Tiede, Verghese Mathew, Kirk N. Garratt, Ryan J. Lennon, David Holmes, Charanjit Rihal

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The AngioJet thrombectomy device removes thrombus by creating a negative pressure and causing fragmentation of the thrombus. The objective was to study the safety and efficacy of this thrombectomy device during coronary interventions and to report the results of our experience. We studied 72 patients (mean age, 64.9 ± 12.6 years; 79% males) who had an AngioJet procedure during coronary intervention; 33 (46%) had vein graft intervention. All patients had angiographic thrombus. Most patients presented either with unstable angina (54%) or acute myocardial infarction (32%) within 24 hr. The procedural success was high with AngioJet (93%). TIMI grade 3 flow was achieved in 79% of lesions treated with AngioJet. In-hospital mortality was 1.4%, death/Q-wave myocardial infarction was 4.2%, and the composite endpoint of death and Q-wave myocardial infarction/revascularization was 5.6% for patients undergoing AngioJet. Subgroup analysis of patients with vein graft intervention demonstrated high procedural success in those undergoing AngioJet (91%). At 1-year follow-up of the successful percutaneous interventions with AngioJet, the mortality, death/Q-myocardial infarction, and composite endpoint rates were 10%, 13.3%, and 35.5%, respectively. Long-term event-free survival was worse in vein graft interventions. The incidence of death, death/ myocardial infarction, or composite endpoints at 1 year was 16%, 19%, and 46%, respectively. High procedural success can be achieved with the AngioJet thrombectomy device in lesions containing thrombus. It is effective in both native coronary arteries and vein graft interventions. However, the long-term outcome of patients with vein graft intervention was worse.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume56
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Thrombectomy
Thrombosis
Myocardial Infarction
Veins
Transplants
Equipment and Supplies
Coronary Vessels
Myocardial Revascularization
Unstable Angina
Hospital Mortality
Disease-Free Survival
Safety
Pressure
Mortality
Incidence

Keywords

  • AngioJet
  • Coronary intervention
  • Thrombectomy
  • Thrombus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Rheolytic thrombectomy with AngioJet in thrombus-containing lesions. / Singh, Mandeep; Tiede, Daniel J.; Mathew, Verghese; Garratt, Kirk N.; Lennon, Ryan J.; Holmes, David; Rihal, Charanjit.

In: Catheterization and Cardiovascular Interventions, Vol. 56, No. 1, 2002, p. 1-7.

Research output: Contribution to journalArticle

Singh, Mandeep ; Tiede, Daniel J. ; Mathew, Verghese ; Garratt, Kirk N. ; Lennon, Ryan J. ; Holmes, David ; Rihal, Charanjit. / Rheolytic thrombectomy with AngioJet in thrombus-containing lesions. In: Catheterization and Cardiovascular Interventions. 2002 ; Vol. 56, No. 1. pp. 1-7.
@article{3733d2f04e2c4976bc58d106f3b527b1,
title = "Rheolytic thrombectomy with AngioJet in thrombus-containing lesions",
abstract = "The AngioJet thrombectomy device removes thrombus by creating a negative pressure and causing fragmentation of the thrombus. The objective was to study the safety and efficacy of this thrombectomy device during coronary interventions and to report the results of our experience. We studied 72 patients (mean age, 64.9 ± 12.6 years; 79{\%} males) who had an AngioJet procedure during coronary intervention; 33 (46{\%}) had vein graft intervention. All patients had angiographic thrombus. Most patients presented either with unstable angina (54{\%}) or acute myocardial infarction (32{\%}) within 24 hr. The procedural success was high with AngioJet (93{\%}). TIMI grade 3 flow was achieved in 79{\%} of lesions treated with AngioJet. In-hospital mortality was 1.4{\%}, death/Q-wave myocardial infarction was 4.2{\%}, and the composite endpoint of death and Q-wave myocardial infarction/revascularization was 5.6{\%} for patients undergoing AngioJet. Subgroup analysis of patients with vein graft intervention demonstrated high procedural success in those undergoing AngioJet (91{\%}). At 1-year follow-up of the successful percutaneous interventions with AngioJet, the mortality, death/Q-myocardial infarction, and composite endpoint rates were 10{\%}, 13.3{\%}, and 35.5{\%}, respectively. Long-term event-free survival was worse in vein graft interventions. The incidence of death, death/ myocardial infarction, or composite endpoints at 1 year was 16{\%}, 19{\%}, and 46{\%}, respectively. High procedural success can be achieved with the AngioJet thrombectomy device in lesions containing thrombus. It is effective in both native coronary arteries and vein graft interventions. However, the long-term outcome of patients with vein graft intervention was worse.",
keywords = "AngioJet, Coronary intervention, Thrombectomy, Thrombus",
author = "Mandeep Singh and Tiede, {Daniel J.} and Verghese Mathew and Garratt, {Kirk N.} and Lennon, {Ryan J.} and David Holmes and Charanjit Rihal",
year = "2002",
doi = "10.1002/ccd.10176",
language = "English (US)",
volume = "56",
pages = "1--7",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Rheolytic thrombectomy with AngioJet in thrombus-containing lesions

AU - Singh, Mandeep

AU - Tiede, Daniel J.

AU - Mathew, Verghese

AU - Garratt, Kirk N.

AU - Lennon, Ryan J.

AU - Holmes, David

AU - Rihal, Charanjit

PY - 2002

Y1 - 2002

N2 - The AngioJet thrombectomy device removes thrombus by creating a negative pressure and causing fragmentation of the thrombus. The objective was to study the safety and efficacy of this thrombectomy device during coronary interventions and to report the results of our experience. We studied 72 patients (mean age, 64.9 ± 12.6 years; 79% males) who had an AngioJet procedure during coronary intervention; 33 (46%) had vein graft intervention. All patients had angiographic thrombus. Most patients presented either with unstable angina (54%) or acute myocardial infarction (32%) within 24 hr. The procedural success was high with AngioJet (93%). TIMI grade 3 flow was achieved in 79% of lesions treated with AngioJet. In-hospital mortality was 1.4%, death/Q-wave myocardial infarction was 4.2%, and the composite endpoint of death and Q-wave myocardial infarction/revascularization was 5.6% for patients undergoing AngioJet. Subgroup analysis of patients with vein graft intervention demonstrated high procedural success in those undergoing AngioJet (91%). At 1-year follow-up of the successful percutaneous interventions with AngioJet, the mortality, death/Q-myocardial infarction, and composite endpoint rates were 10%, 13.3%, and 35.5%, respectively. Long-term event-free survival was worse in vein graft interventions. The incidence of death, death/ myocardial infarction, or composite endpoints at 1 year was 16%, 19%, and 46%, respectively. High procedural success can be achieved with the AngioJet thrombectomy device in lesions containing thrombus. It is effective in both native coronary arteries and vein graft interventions. However, the long-term outcome of patients with vein graft intervention was worse.

AB - The AngioJet thrombectomy device removes thrombus by creating a negative pressure and causing fragmentation of the thrombus. The objective was to study the safety and efficacy of this thrombectomy device during coronary interventions and to report the results of our experience. We studied 72 patients (mean age, 64.9 ± 12.6 years; 79% males) who had an AngioJet procedure during coronary intervention; 33 (46%) had vein graft intervention. All patients had angiographic thrombus. Most patients presented either with unstable angina (54%) or acute myocardial infarction (32%) within 24 hr. The procedural success was high with AngioJet (93%). TIMI grade 3 flow was achieved in 79% of lesions treated with AngioJet. In-hospital mortality was 1.4%, death/Q-wave myocardial infarction was 4.2%, and the composite endpoint of death and Q-wave myocardial infarction/revascularization was 5.6% for patients undergoing AngioJet. Subgroup analysis of patients with vein graft intervention demonstrated high procedural success in those undergoing AngioJet (91%). At 1-year follow-up of the successful percutaneous interventions with AngioJet, the mortality, death/Q-myocardial infarction, and composite endpoint rates were 10%, 13.3%, and 35.5%, respectively. Long-term event-free survival was worse in vein graft interventions. The incidence of death, death/ myocardial infarction, or composite endpoints at 1 year was 16%, 19%, and 46%, respectively. High procedural success can be achieved with the AngioJet thrombectomy device in lesions containing thrombus. It is effective in both native coronary arteries and vein graft interventions. However, the long-term outcome of patients with vein graft intervention was worse.

KW - AngioJet

KW - Coronary intervention

KW - Thrombectomy

KW - Thrombus

UR - http://www.scopus.com/inward/record.url?scp=0036238177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036238177&partnerID=8YFLogxK

U2 - 10.1002/ccd.10176

DO - 10.1002/ccd.10176

M3 - Article

C2 - 11979522

AN - SCOPUS:0036238177

VL - 56

SP - 1

EP - 7

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -